Anticoagulation after typical atrial flutter ablation

Cover Page

Cite item

Full Text

Abstract

The specifics of the anticoagulant therapy after radiofrequency ablation of the cavotricuspid isthmus have not been sufficiently studied, therefore, the recommendations for prescribing the anticoagulant therapy usually do not distinguish between atrial flutter and atrial fibrillation. In contrast to the case of atrial fibrillation, the effectiveness of the interventional treatment for typical atrial flutter reaches 90%. This procedure may save the patient from a long-term anticoagulant therapy in the absence of recurrence of typical atrial flutter. The decision to stop the anticoagulant therapy after successful radiofrequency ablation of the cavotricuspid isthmus should take into account the potential induction of atrial fibrillation in patients undergoing the interventional treatment. In addition to the CHA2DS2-VASc scale, which characterizes the patient's comorbidity, it is important to take into account the echocardiographic morphofunctional criteria to assess the risk of atrial fibrillation. Currently, this protocol is not regulated in the clinical guidelines. The analysis of the literature data and the authors' own experience allow us to conclude that the optimal time for stopping the anticoagulant therapy is a relapse-free period of 3–4 months after the radiofrequency ablation of the cavotricuspid isthmus, since it is at this time that the effectiveness of the interventional treatment can be objectified.

About the authors

Irina A. Bulavina

Buyanov City Clinical Hospital

Email: doctoroirb@yandex.ru
ORCID iD: 0000-0002-6267-3724
SPIN-code: 1275-2773

MD, cardiologist at cardiac surgery department

Russian Federation, Moscow

Igor A. Khamnagadaev

Endocrinology Research Centre; The Russian National Research Medical University named after N.I. Pirogov

Email: i@khamnagadaev.ru
ORCID iD: 0000-0002-9247-4523
SPIN-code: 6338-4990

MD, PhD

Russian Federation, Moscow; Moscow

Igor I. Khamnagadaev

Belgorod State National Research University

Email: khamnaga@yandex.ru
ORCID iD: 0000-0001-8541-0364
SPIN-code: 6883-5175

MD, PhD, Professor

Russian Federation, Belgorod

Mikhail L. Kokov

Russian State Agrarian University — Moscow Timiryazev Agricultural Academy

Email: mikhailkokov@gmail.com
ORCID iD: 0000-0003-4766-5213

врач-рентгенолог, кафедра физиологии растений, МНС 

Russian Federation, Moscow

Aleksandr V. Troitskiy

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency

Email: dr.troitskiy@gmail.com
ORCID iD: 0000-0003-2143-8696
SPIN-code: 2670-6662

MD, PhD

Russian Federation, 28 Orekhovy boulevard, 115682 Moscow

Aleksandr S. Zotov

Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency

Author for correspondence.
Email: zotov.alex.az@gmail.com
ORCID iD: 0000-0003-0494-0211
SPIN-code: 9315-6570

MD, PhD

Russian Federation, 28 Orekhovy boulevard, 115682 Moscow

Leonid S. Kokov

Sklifosovsky Research Institute of Emergency Medicine; Moscow State University of Medicine and Dentistry named after A.I. Evdokimov

Email: lskokov@mail.ru
ORCID iD: 0000-0002-3167-3692
SPIN-code: 1655-5794

MD, PhD, Professor, Academician of the Russian Academy of Sciences

Russian Federation, Moscow; Moscow

Maria A. Shkolnikova

The Russian National Research Medical University named after N.I. Pirogov

Email: Arrithmolog@gmail.com
ORCID iD: 0000-0001-7115-0186
SPIN-code: 9051-7107

MD, PhD, Professor

Russian Federation, Moscow

References

  1. Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am College Cardiol. 2000;36(7):2242–2246. doi: 10.1016/s0735-1097(00)00982-7
  2. Колбин А.С., Татарский Б.А., Бисерова И.Н., и др. Социально-экономическое бремя мерцательной аритмии в Российской Федерации // Клиническая фармакология и терапия. 2010. Т. 19, № 4. С. 17–22. [Kolbin AS, Tatarsky BA, Biserova IN, et al. Socio-economic burden of atrial fibrillation in the Russian Federation. Clinical pharmacology and therapy. 2010;19(4): 17–22. (In Russ).]
  3. Прокаева Т.А., Жигаев Г.Ф., Прокаев Е.М., и др. Медико-экономическая оценка оказания стационарной помощи при мозговом инсульте // Бюллетень Восточно-Сибирского научного центра Сибирского отделения Российской академии медицинских наук. 2015. Т. 2, № 102. С. 122–125. [Prokaeva TA, Zhigaev GF, Prokaev EM, et al. Medico-economic assessment of inpatient care for cerebral stroke. Bulletin East Siberian Scientific Center Siberian Branch Russian Academy Medical Sciences. 2015;2(102):122–125. (In Russ).]
  4. Expósito V, Rodríguez-Entem F, González-Enríquez S, et al. Stroke and systemic embolism after successful ablation of typical atrial flutter. Clin Cardiol. 2016;39:347–351. doi: 10.1002/clc.22538
  5. McWilliam JA. Fibrillar contraction of the heart. J Physiology. 1887;8(5):296–310. doi: 10.1113/jphysiol.1887.sp000261
  6. Jolly WA, Ritchie WT. Auricular flutter and fibrillation. Heart. 1911;2:177–221.
  7. Wells JL, MacLean WA, James TN, et al. Characterization of atrial flutter. Studies in man after open heart surgery using fixed atrial electrodes. Circulation. 1979;60(3):665–673. doi: 10.1161/01.cir.60.3.665
  8. Scheinman MM, Cheng J, Yang Y. Mechanisms and clinical implications of atypical atrial flutter. J Cardiovascular Electrophysiol. 1999;10(8):1153–1157. doi: 10.1111/j.1540-8167.1999.tb00288
  9. Shah SR, Luu SW, Calestino M, et al. Management of atrial fibrillation-flutter: Uptodate guideline paper on the current evidence. J Community Hosp Intern Med Perspect. 2018; 8(5):269–275. doi: 10.1080/20009666.2018.1514932
  10. Gula LJ, Redfearn DP, Jenkyn KB, et al. Elevated incidence of atrial fibrillation and stroke in patients with atrial flutter: A population-based study. Can J Cardiol. 2018;34(6):774–783. doi: 10.1016/j.cjca.2018.01.001
  11. Attanasio P, Budde T, Lacour P, et al. Catheter ablation of atrial flutter: A survey focusing on post ablation oral anticoagulation management and ECG monitoring. Pacing Clin Electrophysiol. 2017;40(7):788-793. doi: 10.1111/pace.13122
  12. Krisai P, Roten L, Zeljkovic I, et al. Prospective evaluation of a standardized screening for atrial fibrillation after ablation of cavotricuspid isthmus dependent atrial flutter. J Clin Med. 2021;10(19):4453. doi: 10.3390/jcm10194453
  13. Escobar C, Castrejón S, de Oca RM, et al. Common atrial flutter catheter ablation without discontinuing oral anticoagulation. Future Cardiol. 2017;13(5):429–432. doi: 10.2217/fca-2017-0007
  14. Ревишвили А.Ш., Рзаев Ф.Г., Горев М.В., и др. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации. Москва, 2017. 211 с. [Revishvili AS, Rzaev FG, Gorev MV, et al. Diagnosis and treatment of atrial fibrillation. Clinical recommendations. Moscow; 2017. 211 р. (In Russ).]
  15. Hindricks G, Potpara T, Dagres N, et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. doi: 10.1093/eurheartj/ehab648
  16. Verma A, Ha AC, Kirchhof P, et al. The optimal anti-coagulation for enhanced-risk patients post-catheter ablation for atrial fibrillation (OCEAN) trial. Am Heart J. 2018;197:124–132. doi: 10.1016/j.ahj.2017.12.007
  17. Romero J, Cerrud‐Rodriguez RC, Diaz JC, et al. Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: A systematic review and meta‐analysis. J Cardiovasc Electrophysiol. 2019;30(8):1250–1257. doi: 10.1111/jce.14052
  18. Själander S, Holmqvist F, Smith JG, et al. Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation. JAMA Cardiol. 2017; 2(2):146–152. doi: 10.1001/jamacardio.2016.4179
  19. Proietti R, Al-Turki A, Di Biase L, et al. Anticoagulation after catheter ablation of atrial fibrillation: an unnecessary evil? A systematic review and meta‐analysis. J Cardiovascular Electrophysiology. 2019;30(4):468–478. doi: 10.1111/jce.13822
  20. Warchoł СI, Bińkowski BJ, Kucejko T, et al. A retrospective study of atrial fibrillation following cavotricuspid isthmus ablation for atrial flutter. Med Sci Monit. 2019;25:3316. doi: 10.12659/MSM.912918
  21. Calkins H, Hindricks G, Cappato R, et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14(10):275–444. doi: 10.1016/j.hrthm.2017.05.012
  22. Голицын С.П., Панченко Е.П., Кропачева Е.С., и др. Евразийские клинические рекомендации по диагностике и лечению фибрилляции предсердий. 2020. [Golitsyn SP, Panchenko EP, Kropacheva ES, et al. Eurasian Clinical Guidelines for the diagnosis and treatment of atrial fibrillation. 2020. (In Russ).]
  23. Nunes-Ferreira A, Alves M, Lima da Silva G, et al. Anticoagulation after typical atrial flutter ablation: Systematic review and meta‐analysis. Pacing Clin Electrophysiol. 2021;44(10): 1701–1710. doi: 10.1111/pace.14342
  24. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. New Eng J Med. 2017;376(17):1627–1636. doi: 10.1056/NEJMc1707247
  25. Celikyurt U, Knecht S, Kuehne M, et al. Incidence of new-onset atrial fibrillation after cavotricuspid isthmus ablation for atrial flutter. Ep Europace. 2017;19(11):1776–1780. doi: 10.1093/europace/euw343
  26. Alqam BM, von Edwins KN, Devabhaktuni S, et al. Oral anticoagulation discontinuation following catheter ablation of typical atrial flutter. J Innov Card Rhythm Manag. 2021;12(7):4595. doi: 10.19102/icrm.2021.120703
  27. Maskoun W, Pino MI, Ayoub K, et al. Incidence of atrial brillation after atrial utter ablation. JACC Clin Electrophysiol. 2016;2(6):682–690. doi: 10.1016/j.jacep.2016.03.014
  28. Jin MN, Song C, Kim TH, et al. CHA2DS2-VASCs core in the prediction of ischemic stroke in patients after radiofrequency catheter ablation of typical atrial flutter. Yonsei Med J. 2018; 59:236–242. doi: 10.3349/ymj.2018.59.2.236
  29. Higashiyama A, Kokubo Y, Watanabe M, et al. Echocardiographic parameters and the risk of incident atrial fibrillation: The SUITA study. J Epidemiol. 2020;30(4):183–187. doi: 10.2188/jea.JE20180251
  30. Olsen FJ, Møgelvang R, Jensen GB, et al. Relationship between left atrial functional measures and incident atrial fibrillation in the general population: The Copenhagen City Heart Study. Cardiovascul Imaging. 2019;12(6):981–989. doi: 10.1016/j.jcmg.2017.12.016
  31. Giehm-Reese M, Johansen MN, Kronborg MB, et al. Discontinuation of oral anticoagulation and risk of stroke and death after ablation for typical atrial flutter: A nation-wide Danish cohort study. Int J Cardiol. 2021;333:110–116. doi: 10.1016/j.ijcard.2021.02.057

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Electrocardiogram (25 mm/s). Typical atrial flutter. FF-waves are clearly seen in leads II, III and aVF. Tachycardia cycle length — 240 ms (FF), 3:1 conduction.

Download (2MB)
Indexing metadata

Copyright (c) 2023 Bulavina I.A., Khamnagadaev I.A., Khamnagadaev I.I., Kokov M.L., Troitskiy A.V., Zotov A.S., Kokov L.S., Shkolnikova M.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies